Post-transcriptional control of HIF-1α by MBNL1 restrains hypoxia-driven stemness in GBM [0.03%]
MBNL1对HIF-1α的转录后调控可限制GBM中缺氧驱动的干细胞特性
Blair P Rendina,Fahim Ahmad,Luka Akerman et al.
Blair P Rendina et al.
MBNL1 binds the HIF-1α 3'UTR to promote rapid mRNA decay, thereby limiting HIF-1 activity and hypoxia-induced stemness in glioblastoma. Using patient-derived glioma stem cells, we show that MBNL1 loss stabilizes HIF-1α mRNA and increases ...
Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection [0.03%]
多组学分析揭示乳腺肿瘤异质性和免疫治疗预测模型以实现精准医疗和早期检测
Zhenxiong Zhao,Zhencang Zheng,Shenglu Jiang et al.
Zhenxiong Zhao et al.
Background: Intratumoral heterogeneity contributes to therapy resistance and immune evasion in breast cancer, making treatment strategies more complex. This study integrates single-cell RNA sequencing (scRNA-seq), spatial...
IFNβ-pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6C+myeloid cells [0.03%]
I型干扰素-pSTAT1-IRF1轴通过诱导免疫原性Ly6C+髓系细胞控制结直肠肿瘤发生
Yan Li,Yanmin Wu,Liyan Liang et al.
Yan Li et al.
It has been extensively studied that IFN-I inhibits tumor progression through their intrinsic functions in tumor cells, of which, regulating tumor cell immunogenicity is a critical way. Besides to tumor cells, myeloid cells also comprise a ...
Filamin a binds deleted in liver cancer 1 (DLC1) to promote its tumor suppressor activity and inhibit the SRF coactivator MRTF-A [0.03%]
Filamin A 结合肝癌缺失基因 1(DLC1) 可增强其肿瘤抑制活性并抑制肌环指蛋白 SRF 协同激活蛋白 MRTF-A
Michael Sergeev,Melanie A Meier,Petra Wohlleben et al.
Michael Sergeev et al.
Filamin A (FLNA) is an actin binding protein that organizes the cytoskeleton and controls many fundamental biological processes, such as cell migration and adhesion. The interaction between FLNA and the Myocardin-related transcription facto...
OTUD4-ZMYND8-DDX3X Axis Drives Immunosuppressive Microenvironment in Spinal Metastases of Triple-Negative Breast Cancer [0.03%]
乳腺三阴性癌脊柱转移瘤免疫抑制微环境中的OTUD4-ZMYND8-DDX3X轴驱动机制
Bing Liang,Annan Hu,Hongwei Lu et al.
Bing Liang et al.
Triple-negative breast cancer (TNBC) exhibits a high propensity for spinal metastasis, leading to severe morbidity and limited therapeutic responses. However, the molecular mechanisms driving spinal colonization remain poorly defined. Here,...
Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer [0.03%]
FGFR4抑制剂(H3B-6527)联合奥沙利铂提高胃癌疗效的机制研究
Nadeem Bhat,Mohammed Soutto,Zheng Chen et al.
Nadeem Bhat et al.
Oxaliplatin, a platinum-based anticancer drug, is commonly used to treat gastrointestinal cancers, including gastric cancer. However, resistance to platinum-based therapies often leads to poor clinical outcomes for gastric cancer patients. ...
Exposure to diesel particulates induces an immunosuppressive microenvironment that promotes the progression of lung cancer [0.03%]
柴油颗粒物的暴露诱导免疫抑制微环境促进肺癌进展
Marie-Laure Delhez,Maëlle Bosmans,Lucia Rodriguez Rodriguez et al.
Marie-Laure Delhez et al.
A comprehensive understanding of the mechanisms by which air pollutant exposure drives cancer progression remains incomplete. Particulate matter has been shown to induce genotoxicity and mutagenesis through oxidative stress both in vivo and...
Dynasore as a dual modulator of lipid rafts and cell death in pancreatic cancer [0.03%]
dynasore作为脂筏和细胞死亡的双重调节剂在胰腺癌中的作用
Jakob S Hamilton,Rekha R Garg,Ryan M Thomas
Jakob S Hamilton
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States and predicted to soon surpass colorectal cancer as the second. The lack of screening tests, advanced stage at diagnosis, and res...
Corrigendum to "P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9" [Neoplasia, volume 23 (2021) 304325] [0.03%]
“P53独立的p53通路的部分恢复：ERK1/2和CDK9对ATF4转录调节通过在突变的p53肿瘤中的作用”[Neoplasia, volume 23 (2021) 304-325]的勘误通知
Xiaobing Tian,Nagib Ahsan,Amriti Lulla et al.
Xiaobing Tian et al.
Published Erratum
Neoplasia (New York, N.Y.). 2025 Nov 14:71:101249. DOI:10.1016/j.neo.2025.101249 2025
Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer [0.03%]
口服生物利用的ITRI-148降解雄激素受体变异体并克服前列腺癌去势抵抗中的抗雄激素耐药性
Chiu-Lien Hung,Wen-Ning Hsu,Tsan-Chun Wang et al.
Chiu-Lien Hung et al.
Androgen receptor (AR) signaling remains a key driver of castration-resistant prostate cancer (CRPC), with AR splice variants like AR-V7 contributing to resistance against second-generation antiandrogens. Targeting the AR N-terminal domain ...